CTIS2024-514339-87-00进行中（未招募）1 期
VMX-C001-02
VarmX B.V.0 个研究点目标入组 12 人开始时间: 2024年5月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.MedDRA version: 20.0Level: PTClassification code: 10009773Term: Coagulation factor X level Class: 100000004848CTIS2023-507059-32-00VarmX B.V.48
招募中
1 期
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)CTIS2024-513329-22-00Kyverna Therapeutics Inc.32
招募中
1 期
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic MalignanciesCTIS2022-501797-19-00AvenCell Europe GmbH60
进行中（未招募）
1 期
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 yearsCTIS2023-506396-94-00Osivax48
招募中
1 期
Safety, pharmacokinetics, and preliminary efficacy of AMX-500 in metastatic castration resistant prostate cancer (mCRPCCTIS2023-503495-24-00Sanofi-Aventis Recherche & Developpement271